-
Deltarasin HCl
- names:
2-[4-[(2S)-2-(2-phenyl-1H-benzimidazol-1-yl)-2-(4-piperidinyl)ethoxy]phenyl]-1-(phenylmethyl)-1H-benzimidazole, trihydrochloride
- CAS号:
1440898-82-7
MDL Number: - MF(分子式): C40H40Cl3N5O MW(分子量): 713.144
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | Deltarasin HCl |
| 英文别名 | Deltarasin HCl; Deltarasin hydrochloride |
| CAS号 | 1440898-82-7 |
| Inchi | InChI=1S/C40H37N5O.3ClH/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31;;;/h1-22,30,38,41H,23-28H2;3*1H/t38-;;;/m1.../s1 |
| InchiKey | NCIOVAYUMQEQEU-VKZSUDIWSA-N |
| 分子式 Formula | C40H40Cl3N5O |
| 分子量 Molecular Weight | 713.144 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Deltarasin HCl(CAS:1440898-82-7 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Deltarasin is a high affinity PDEδ-KRAS interaction inhibitor. Deltarasin can inhibit KRAS-PDEδ interactions by binding to a hydrophobic pocket on PDEδ, resulting in the impairment of cell growth, KRAS activity, and RAS/RAF signaling in human pancreatic ductal adenocarcinoma cell lines. The anti-cancer cell activity of deltarasin can be enhanced by simultaneously blocking "tumor protective" autophagy, but inhibited if combined with an anti-oxidant. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Leung ELH, Luo LX, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ, Ward DC, Liu L. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death Dis. 2018 Feb 13;9(2):216. doi: 10.1038/s41419-017-0065-9. PubMed PMID: 29440631; PubMed Central PMCID: PMC5833846. |
| [2]Dietrich P, Koch A, Fritz V, Hartmann A, Bosserhoff AK, Hellerbrand C. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402. [Epub ahead of print] PubMed PMID: 29275358. |
| [3] Gulyás G, Radvánszki G, Matuska R, Balla A, Hunyady L, Balla T, Várnai P. Plasma membrane phosphatidylinositol 4-phosphate and 4,5-bisphosphate determine the distribution and function of K-Ras4B but not H-Ras proteins. J Biol Chem. 2017 Nov 17;292(46):18862-18877. doi: 10.1074/jbc.M117.806679. Epub 2017 Sep 22. PubMed PMID: 28939768; PubMed Central PMCID: PMC5704471. |
| [4] Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, Nikolouli E, Spiropoulou N, Papadakis A, Papadia K, Voulgaridis A, Harokopos V, Stamou P, Meiners S, Eickelberg O, Snyder LA, Antimisiaris SG, Kardamakis D, Psallidas I, Marazioti A, Stathopoulos GT. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205. PubMed PMID: 28508873; PubMed Central PMCID: PMC5440809. |
| [5] Papke B, Murarka S, Vogel HA, Martín-Gago P, Kovacevic M, Truxius DC, Fansa EK, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens PI. Identification of pyrazolopyridazinones as PDEδ inhibitors. Nat Commun. 2016 Apr 20;7:11360. doi: 10.1038/ncomms11360. PubMed PMID: 27094677; PubMed Central PMCID: PMC4843002. |
6: Zimmermann G, Schultz-Fademrecht C, Küchler P, Murarka S, Ismail S, Triola G, Nussbaumer P, Wittinghofer A, Waldmann H. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem. 2014 Jun 26;57(12):5435-48. doi: 10.1021/jm500632s. Epub 2014 Jun 11. PubMed PMID: 24884780.7: Baker NM, Der CJ. Cancer: Drug for an 'undruggable' protein. Nature. 2013 May 30;497(7451):577-8. doi: 10.1038/nature12248. Epub 2013 May 22. PubMed PMID: 23698372; PubMed Central PMCID: PMC4902159.8: Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI, Waldmann H. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205. Epub 2013 May 22. PubMed PMID: 23698361.9: Tamanoi F, Lu J. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. Enzymes. 2013;34 Pt. B:181-200. doi: 10.1016/B978-0-12-420146-0.00008-1. Epub 2013 Nov 7. Review. PubMed PMID: 25034105.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


